When choosing to include brimonidine in an overall rosacea management plan, clinicians can maximize results by following the pneumonic A ,E, I, O, U, according to a group of dermatologists with hands-on experience treating patients with brimonidine.
Their recommendations, published in the Journal of Drugs in Dermatology, included these general steps: Assess the clinical features of rosacea, Educate patients about their condition and brimonidine therapy, Inhibit inflammation caused by poor skin care, Optimize brimonidine application techniques, and Understand options for managing worsening redness.
Data suggest that 10%-20% of these patients report a “rebound,” traditionally defined as an emergence or reemergence of symptoms that occurs after discontinuation of treatment, the authors noted.
They argue that “rebound” is inaccurate terminology, and that new terminology to describe changes in redness is needed to capture the complexities of the treatment process.
Read the full article at ( J. Drugs Dermatol. 2015;14:33-40 ).
dermnews@frontlinemedcom.com
